14/15 Conduit Street
London W1S 2XJ
United Kingdom
https://www.tizianalifesciences.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 9
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Gabriele Marco Antonio Cerrone M.B.A. | Founder, Executive Chairman & Interim CEO | 444k | N/A | 1972 |
Dr. Andrea Brancale | Scientific Founder | N/A | N/A | N/A |
Mr. Richard Clarkson Ph.D. | Scientific Founder | N/A | N/A | N/A |
Mr. Andrew Westwell Ph.D. | Scientific Founder | N/A | N/A | N/A |
Ms. Keeren Shah | Chief Financial Officer | N/A | N/A | 1976 |
Dr. Matthew W. Davis M.D., R.Ph. | COO & Chief Medical Officer | N/A | N/A | N/A |
Dr. William A. Clementi Ph.D., Pharm.D. | Chief Development Officer | N/A | N/A | N/A |
Dr. Napoleone Ferrara M.D. | Member of Scientific Advisory Board | N/A | N/A | 1958 |
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.
Tiziana Life Sciences Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.